(S008) Use of Mobile Devices for Creation of Survivorship Care Plans

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.

Christine E. Hill-Kayser, MD, Carolyn Vachani, AOCN, Margaret K. Hampshire, RN, Gloria A. DiLullo, APN, James M. Metz, MD; Perelman School of Medicine, University of Pennsylvania

Introduction: Cancer survivors may experience myriad late effects, and the Institute of Medicine recommends that survivorship care plans be provided to all. This study explores the willingness of health care providers (HCPs) and survivors to utilize mobile devices (MDs) for this purpose.

Methods: We launched and made an internet tool publically available for the creation of survivorship care plans in 2007. Available at www.livestrongcareplan.com and through the OncoLink website, it provides customized guidelines for survivor care and is free for use by survivors and HCPs worldwide. With the ninth iteration of the care plan tool, launched in May 2012, the tool became available in a mobile use format. The tool is free and accessible via Apple iPhone and iPad.

Results: Since the launch of the internet-based tool in 2007, it has been used to create 34,669 care plans. Overall, HCPs have created about 40% of them. The demographics of survivors for whom care plans have been created have remained relatively stable (75% women, 81% Caucasian, median age 51 years, with breast cancer being the most common diagnosis). From May 2012 to October 2013, 11,946 total plans were created, 645 (5%) of which were created using MDs. Of the MD-created plans, the majority (97%) was created by survivors or their friends and families, with only 3% being created by HCPs. Of the users of the MD plan, 74% was female and 86% was Caucasian, with a median age at diagnosis of 48 years and a median current age of 52 years. The most common diagnosis for which MD plans were completed was breast cancer (42%), followed by lymphoma (5%), colon cancer (4%), and lung cancer (4%). Of all MD users, 11% reported having received some type of survivorship information, and 15% reported having received a written treatment summary; 4% had previously created or received a LIVESTRONG Care Plan. The median time for completion of the patient version of the MD plan was 8:07 minutes and 6:27 minutes for the HCP version. The experience with using the MD tool was evaluated as good-excellent by 92% of users.

Conclusions: For users with access, MDs appear to be feasible tools for care plan creation. Based on preliminary data, this represents a novel way to disseminate useful information to cancer survivors, particularly those who may have MD access but not computer access. Future plans will include efforts to inform HCPs about the existence of the MD plan, which may be useful in clinical settings when tablet devices are available.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content